Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

AstraZeneca gets US boost for bladder cancer drug

Drug group gets "breakthrough therapy" designation for durvalumab in the US
AstraZeneca gets US boost for bladder cancer drug
AstraZeneca is said to have received three "breakthrough therapy" designations for cancer drugs

Shares in drug group AstraZeneca (LON:AZN) were healthier after it received a US boost for a bladder cancer treatment.

The stock rose 70.5p, or nearly 1.7%, to 4254.5p as the Food & Drug Administration (FDA) designated its durvalumab drug as a "breakthrough therapy".

Breakthrough therapy designation (BTD) is designed to speed up development of drugs for serious conditions which have shown encouraging early clinical results, improvements over existing treatments or potential to address significant unmet medical need.

AstraZeneca's senior vice-president and head of immuno-oncology in global medicines development, Robert Iannone, said: "Metastatic bladder cancer is an area of enormous unmet medical need.

"We are encouraged by this breakthrough therapy designation. We look forward to working closely with the FDA to bring durvalumab to bladder cancer patients as soon as possible."

The designation, based on early clinical data from a phase one trial in patients with advanced urothelial bladder cancer, is said to be the third BTD that AstraZeneca has received for an oncology medicine.

Phil-Waller.jpg


Register here to be notified of future AZN Company articles
View full AZN profile

AstraZeneca Timeline

Related Articles

shutterstock_216375733.jpg
January 24 2017
At the moment, the healthcare firm M Pharma is a work in progress
Drugs
February 06 2017
The hybrid pharma services and drug development group has hit some key milestones over this year as trial results are eyed.
picture of drug research
February 20 2017
“The positive results from this feasibility award may lead to other opportunities to secure additional funding awards to advance the programme further," Dr John Reader, Sareum's chief scientific officer said.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.